Institute Of Hematology & Blood Diseases Hospital, China

This study tested a drug called dasatinib combined with standard chemotherapy in 30 adults newly diagnosed with a specific, aggressive leukemia (Ph+ ALL). The goal was to see if the combination could improve survival and was tolerable. Participants took dasatinib daily for up to …

This early-phase study tested a new treatment called C-CAR088 in 9 people with multiple myeloma that had returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main goal was to check s…

This early-phase study tested a new treatment using lab-grown immune cells (NK cells) in 2 adults with acute myeloid leukemia (AML) that had come back or not responded to standard therapy. The main goal was to see if the treatment is safe and tolerable. Researchers also looked fo…

This study tested a new 9-day treatment plan for people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The treatment combined three drugs: rabbit antithymocyte globulin, cyclosporine, and levamisole. The goal was to see if thi…

This study compares a stem cell transplant to standard chemotherapy for people with high-risk Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if the transplant helps patients live longer. The trial involved 70 participants in China and has already been comp…